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Summary 
The recent finding that CD40L on activated T cells induces interleukin (IL) 12 secretion in hu- 
man peripheral blood monocytes in vitro suggests  that the CD40L-CD40 interaction may be 
of importance in the priming ofT helper (Th) 1-type T  cells. We therefore investigated the in 
vivo relevance of this interaction in an experimental model for a Thl-mediated disease,  the 
hapten reagent (2,4,6-trinitrobenzene sulfonic acid [TNBS])-induced colitis. The administra- 
tion of anti-gp39  (CD40L)  antibodies during the induction phase of the Thl  response pre- 
vented interferon 2r production by lamina propria CD4 + T cells and also clinical and histologi- 
cal evidence of disease.  In contrast, the secretion of IL-4, a Th2-type cytokine, was increased 
after anti-gp39 treatment. In further studies we showed that the prevention of disease  activity 
was caused by an inhibition of IL-12 secretion, as demonstrated by immunohistochemistry. In 
addition, the injection of  recombinant IL-12 p70 heterodimer into TNBS +  anti-gp39-treated 
mice reversed the effect of anti-gp39 and resulted in severe disease  activity. When anti-gp39 
was  given after the disease  was  established, no effect on the disease  activity was observed. In 
conclusion,  we  demonstrated  that  the  CD40L-CD40  interaction is  crucial for the  in  vivo 
priming ofThl T cells via the stimulation oflL-12 secretion by antigen-presenting cells (APC). 
T 
he presence of specific cytokines is  the  major factor 
that influences naive T  cells to become a Thl  (IL-2, 
IFN-~/)  or  a  Th2  T  cell  (IL-4,  IL-5,  IL-6,  IL-10,  and 
IL-13) (for review see reference 1). Thus, IL-4 plays a crit- 
ical role in the priming of Th2 cells (2), and IL-12 alone (3) 
or together with  IFN-~/  (4)  drives naive T  cells  into  the 
Thl  lymphokine-producing phenotype. Various other as- 
pects of APC-T cell interactions, however, may also influ- 
ence Thl/Th2 T  cell development, either directly or via 
an  effect on  cytokine secretion.  The first  aspect  suggests 
differential signaling through the  costimulatory molecules 
B7-1 and B7-2, with B7-1 costimulation leading to a Thl 
phenotype and signaling through B7-2 resulting in a Th2 
phenotype (5, 6). The second aspect involves the density of 
specific  peptide-MHC  class II  complexes  on  the  mem- 
brane of an APC, with a high density of these complexes 
favoring Thl priming and low densities causing Th2 prim- 
ing  (7).  Third,  the  interaction of CD40L on activated T 
cells with CD40 on APC has been implicated to be impor- 
tant in T  cell priming: a very recent in vitro study by Shu 
and co-workers demonstrated that this interaction leads  to 
the secretion of IL-12 by human monocytes, which could 
favor the priming of Thl cells (8). 
We investigated the  in vivo relevance of the  CD40L- 
CD40 interaction for the priming ofThl T  cells in a recently 
developed animal model for chronic intestinal inflammation 
in  the  mouse,  the  hapten  reagent  (2,4,6-trinitrobenzene 
sulfonic acid [TNBS])-induced colitis. This experimental ani- 
mal model has  been shown to be a Thl-mediated disease 
by the  fact that the  infiltrating CD4 +  T  cells secrete pre- 
dominandy IFN-~t.  In  addition,  the  treatment of TNBS- 
induced colitis with antibodies against  IL-12, which regu- 
lates  IFN-~/  secretion as  mentioned above, abrogated the 
disease.  Finally, the colitis was not inducible in IFN-~/-/- 
gene--targeted mice (9).  In this  study we report that treat- 
ment  with  anti-gp39  (CD40L)  antibodies  during the  in- 
duction of Thl-mediated colitis prevented the  disease  as 
well  as  the  occurrence of IFN-~/-secreting T  cells  in  the 
lamina  propria  (LP).  We  further  observed a  decrease  in 
IL-12  production  by  infiltrating  cells  after  this  antibody 
treatment. If we injected rlL-12 into TNBS +  anti-gp39- 
treated mice, the effect of anti-gp39 was reversed, suggest- 
ing  that  in  our  experimental model  for a  Thl-mediated 
disease,  the  interaction  between  CD40L  on  activated  T 
ceils  and  CD40  on APC  is  of crucial importance for the 
priming process during the  differentiation of Thl  T  cells 
but not for later differentiation stages ofThl effector cells. 
Material and Methods 
Induction of Colitis.  Specific  pathogen-free 2-4-too-old female 
SJL/J mice (National Cancer  Institute, Bethesda, MD) were in- 
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(Sigma Chemical Co., St.  Louis,  MO) in 50% ethanol as previ- 
ously described  (9). In control experiments,  mice received 50% 
ethanol alone. The total injection volume was 100 Ixl in both groups. 
Treatment with Anti-gp39  (CD4OL) and IL-12.  After  induction 
of colitis with TNBS, the mice were either treated with 0.5 mg 
ofmonoclonal anti-gp39 (CD40L)  antibody (MR.-l) (10) or ham- 
ster IgG (halgG)  as control (Jackson ImmunoR.esearch Laborato- 
ries, Inc., West Grove, PA) on days 0 and 2. Mouse rlL-12 p70 
heterodimer (100 ng)  (kindly provided by Dr. M. Gately,  Hoff- 
man-LaR.oche, Nutley, NJ)  was injected into some of the anti- 
CD40L-treated mice on days 0, 2, and 4. In addition,  to investi- 
gate late effect of anti-gp39 treatment, we treated a second group 
of mice with anti-gp39 antibodies  at days 7 and 9. 
Immunohistochemistry and  Hematoxylin  and  Eosin (H&E)  Stain- 
ing.  Tissue  samples were frozen on dry ice, and 7-btm cryosec- 
tions were cut according to standard  procedures.  Sections  were 
fixed in cold acetone, Some sections subsequently  underwent the 
standard procedures for H&E staining.  Others were rehydrated in 
PBS, blocked with 2% milk powder in PBS, and incubated with 
anti-IL-  12 p 40 subunit (C 17.8; kindly provided by G. Trinchieri, 
Wistar Institute,  Philadelphia,  PA) for 60 min. After the incuba- 
tion  with  biotinylated  rabbit  anti-rat  antibody  and  with  the 
ABC-HR.PO  solution  (ABC-Kit,  Elite;  Vector  Laboratories, 
Inc., Burlingame,  CA),  the  color reaction was  performed with 
the diaminobenzidine substrate  for alkaline  phosphatase  (Vector 
Laboratories,  Inc.),  and the sections  were  counterstained in 5% 
methyl green,  air dried,  and mounted in Permount (Fisher Scien- 
tific Co., Fair Lawn, NJ). 
Isolation and Culture of LP CD4 + T Cells.  LP lymphocytes were 
isolated from freshly obtained colonic specimens  using a modifi- 
cation of the technique described  by van der Heijden and Stok 
(11). Enriched CD4 + T  cell populations were obtained by nega- 
tive  selection  using mouse CD4 + T  cell isolation  columns (Iso- 
cell;  Pierce  Chemical  Co.,  R.ockford,  IL).  The  resultant  cells 
when analyzed by flow cytometry (FACScan|  Becton Dickinson 
& Co., Mountain View, CA) contained >85% CD4 + cells. Cell 
cultures  of LP CD4 + T  cells were performed as previously de- 
scribed  (9). 
Reagents and mAbs.  Unconjugated and biotinylated rat  anti- 
mouse IL-4 (BVD4-1D11/BVD6-24G2), and IFN-'y (R.4-6A2/ 
XMG1.2)  mAbs were  obtained from PharMingen  (San Diego, 
CA). IL-4 (10  v U/mg by CTLL-2.4 assay) and IFN-y (107 U/mg) 
were purchased  from PharMingen  and  Genzyme Corp.  (Cam- 
bridge,  MA),  respectively.  Purified  hamster  anti-mouse  CD3~ 
(clone  145-2Cll)  and hamster anti-mouse CD28 (clone  37.51) 
antibodies  were bought from PharMingen. 
CytokineAssays.  To  measure  cytokine  production,  10  s LP 
CD4 + T cells were placed in anti-CD3-precoated wells or in un- 
coated control wells,  and  1 b~g/ml soluble  anti-CD28 antibody 
was added to the cells in the anti-CD3e-coated wells.  Culture 
supematants  were removed after  48 h  and assayed for cytokine 
concentration.  Cytokine concentrations were determined by specific 
ELISA according to the manufacturer's  recommendations (Phar- 
Mingen).  ODs were measured on an ELISA reader (model MR. 
5000; Dynatech Laboratories,  Inc., Chantilly,  VA) at a wavelength 
of 490 nm. 
Results and Discussion 
In  Vivo Administration  of Anti-gp39 Antibodies in Mice Pre- 
vents TNBS-induced  Colitis but Does Not Abrogate Established 
Disease.  Previous  studies  in  our  laboratory  have  estab- 
lished  that  similar  to  the  situation  in  the  rat  (12,  13),  in- 
trarectal instillation of TNBS in mice causes a severe chronic 
intestinal inflammation marked by massive diarrhea, weight 
loss, and anal prolapse that mimics some aspects of Crohn's 
disease in humans (9).  This colitis is mediated by Thl-type 
T  cells  since  the  infiiltrating  CD4 +  T  cells  produce  in- 
creased amounts of IFN-y and decreased amounts of IL-4 
compared  with  control  animals.  In  addition,  IFN-y  -/- 
gene-targeted mice did not develop colitis after the appli- 
cation of TNBS, and in vivo administration  of anti-IL-12, 
which  negatively  regulates  IFN-y  expression  (14),  abol- 
ished the disease  (9).  One as yet unanswered question con- 
cerning this animal model for a Thl-mediated disease is the 
nature of the stimuli responsible for the induction of IL-12 
secretion underlying the disease.  Based on recent evidence 
that CD40L on activated T  cells induces IL-12 secretion by 
peripheral blood monocytes in vitro  (8),  we investigated if 
the  CD40L-CD40  interaction  in  this  murine  model  for 
Thl-mediated colitis results in the production of IL-12 by 
APC and thus is involved in the in vivo priming of Thl  T 
cells.  We therefore treated mice with either 0.5 mg of the 
anti-gp39 mAb (MR-l),  0.5 mg of control halgG, or PBS 
0  and  2  d  after the  administration  of TNBS  and  then  as- 
sessed disease activity by monitoring weight changes, histo- 
logical evidence of inflammation, and cytokine production. 
As depicted in Fig. 1 A, the administration of anti-gp39 on 
days 0 and 2 clearly prevented the weight loss caused by the 
rectal instillation of TNBS; thus treated mice also appeared 
healthy as assessed by their activity and absence of diarrhea. 
In addition,  the  typical lymphocytic infiltrates  of TNBS- 
induced colitis (Fig.  1 B), which were previously shown to 
contain  predominantly  CD4 +  T  cells  (9),  were  absent  in 
anti-gp39-treated  mice  (Fig.  1  C).  Finally,  as  depicted  in 
Fig.  1 D,  IFN-',/secretion by anti-CD3/CD28-stimulated 
CD4 + T  cells  of the LP, which is typically upregulated in 
TNBS-induced  colitis,  was reduced to normal levels  after 
the  administration  of anti-gp39,  whereas,  as  illustrated  in 
Fig.  1 E, the secretion of IL-4 was upregulated about five- 
fold  compared  with  cells  from  colitic  mice  treated  with 
control halgG. This effect of anti-gp39 cannot result from 
its  possible inhibitory effect on specific anti-TNP antibody 
production, because in our previous studies, treatment with 
anti-IL-12 increased the serum anti-TNP levels but none- 
theless  abolished the  disease  (Neurath,  M.,  and E.  Stiiber, 
unpublished  observation).  Thus,  in  the  TNBS-induced 
colitis model,  antibody production does not seem to have 
clinical  relevance.  In  contrast  to  the  above-mentioned 
findings,  mice  administered  anti-gp39  antibody  on  day  7 
continued  to  manifest  colitis  marked  by  the  presence  of 
weight  loss,  diarrhea,  and  colonic  inflammation  (data  not 
shown). 
The  Inhibition  of the  CD40-CD40L  Interaction  by  Anti- 
gp39  Antibodies  Prevents  Increased IL-12  Secretion  in  TNBS- 
induced  Colitis.  The effect of the blockage of the CD40L- 
CD40 interaction by anti-gp39 could result from a lack of 
IL-12 production.  To  examine  this  question  directly,  we 
first performed in situ immunohistochemistry for IL-12 on 
frozen  gut  sections  from  untreated  or  anti-gp39-treated 
694  The CD40L-CD40 Interaction and Thl-T Cell Priming d 
untreated 
TNBS 
TNBS+halt~ 
TNB,~,antI.,CD40L 
0 
e 
untrmlted 
TNm 
TNBS + halgG 
TNBS + antkCD40L 
100  200  300  400 
IFN-'y (U/ml)  (U/ml) 
￿9  unfUmulM~l 
500 
IL-4  (Ulml) 
Figure 1.  The administration of anti-gp39 prevents disease activity in 
the TNBS-colitis model in mice. (A) TNBS colitis was induced in three 
SJL/J mice and treated with halgG, anti-CD40L (gp39), or not treated at 
all. Weight changes were monitored for the subsequent 10 d. Treatment 
with 50% ethanol alone does not cause colitis or wasting disease (data not 
shown). (B and C) Colon from mice treated with TNBS plus halgG (/3) 
or anti-CD40L (C) were removed on day 7 after the rectal instillation of 
TNBS, frozen on dry ice, and H&E stains  from frozen sections were per- 
formed according to standard techniques. (D and E) Animals  were treated 
as described in A.  On day 7  after TNBS  administration, colons were 
removed and CD4 § T cells from the LP were prepared as described in 
Materials and Methods. The T  cells were subsequently stimulated with 
anti-CD3/CD28 or were not stimulated at all, and the concentrations of 
[FN-~/(D) or IL-4 (E) were determined after 48 h of culture. 
mice  with  TNBS-induced  colitis.  Second,  we  injected 
rlL-12  p70  heterodimer into  mice  that  were  also  treated 
with TNBS  and anti-gp39. As shown  in Fig. 2, A  and B, 
whereas in control halgG-treated mice,  IL-12 p40 expres- 
sion could clearly be detected within the lymphocytic infil- 
trates, no such expression could be found in anti-gp39 anti- 
body-treated mice.  Second, when  we  administered IL-12 
to  TNBS-  and  anti-gp39-treated  mice,  we  observed  the 
same  disease  pattern  as  in  mice  treated  with  TNBS  and 
halgG alone,  as assessed by weight loss  (Fig.  2  C)  and by 
the appearance of lymphocytic infiltrates (data not shown). 
IL-12  alone  given  without  TNBS  did not  induce  colitis. 
Finally, as illustrated in Fig. 2, D  and E, we found that IL-12 
reverses the effect of the anti-gp39 antibody treatment not 
only in  terms  of disease activity and  histological changes, 
but also in terms of IL-4 and IFN-~/secretion by LP-CD4, 
with the latter even higher in the IL-12/anti-gp39-treated 
animals  compared with  the  control halgG-treated TNBS 
mice. 
Recent  studies  on  the  relevance  of the  CD40L-CD40 
interaction revealed that blocking this interaction abolished 
the B  cell response to T  cell-dependent antigens, the for- 
mation of germinal centers, and the development of B  cell 
memory  (15).  It also was demonstrated that this treatment 
impairs T  cell functions  in  the  murine  collagen type  II- 
induced arthritis model (16),  in acute semiallogenic GVHD 
(17), and in the allospecific CTL reaction (18), that is, reac- 
tions that are believed to be mediated by Thl-type T  cells. 
On  the  other hand,  the  administration of anti-gp39  anti- 
body did not influence Th2 T  cell functions (19). 
The  explanation for  the  impairment  of T  cell function 
that occurs in the absence of a  normal CD40-CD40L  in- 
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tion ofrlL-12. (A and B) SJL/J mice were treated with TNBS plus halgG (A; 200￿  or anti-CD40L (gp39) (B; 400￿  and the large bowels were  re- 
moved on day 7. Cryosections  were stained for the IL-12 p40 subunit as described  in Materials  and Methods. (C) TNBS cohtis was induced in three SJL/J 
mice and additionally  treated with halgG, anti-CD40L (gp39), or anti-CD40L plus rlL-12 (100 ng every 2nd d). Weight changes were monitored for the 
subsequent 10 d. (D and E) Animals were treated as described in C. On day 7 after TNBS administration, colons were removed, and CD4 § T cells 
from the LP were prepared as described in Materials and Methods. The T cells were subsequently stimulated with anti-CD3/CD28 or not stimulated at 
all, and the concentrations oflFN-~ (D) or IL-4 (E) were determined after 48 h of culture. 
teraction could be caused by a diminished B7 expression on 
APC  and  thus  an  inefficient costimulation  of T  cells  (20, 
21). Although this mechanism might be operative in some 
situations, however, it does not explain the fact that block- 
ing of the CD40L-CD40  interaction affects predominantly 
Thl  T  cell functions but leaves Th2 T  cell responses intact. 
An alternative explanation for the T  cell defect observed in 
the  absence  of a  functional  CD40L-CD40  interaction  is 
provided  by  the  results  reported  here.  In  our  model  of 
TNBS-induced colitis, the administration of anti-gp39 an- 
tibodies resulted in an inhibition of IL-12 production and 
consequently the lack ofThl  T  cell priming. Nevertheless, 
priming of Th2  T  cells, as assessed by IL-4 secretion, was 
increased, which  argues against an impaired costimulation 
ofT  cells. The link between the decrease in IL-12 produc- 
tion and the lack of Thl  T  cell priming was further dem- 
onstrated by the fact that the  effect of anti-gp39 antibody 
was totally reversible by the coadministration ofrlL-12 p70 
heterodimer.  Taken  together,  these  data  strongly suggest 
that  the  selective T  cell functional  impairment  occurring 
after  the  disruption  of the  CD40L-CD40  interaction  is 
mainly caused by its effect on IL-12 secretion. Importantly, 
we did not observe an effect ofanti-gp39 antibody on TNBS- 
induced colitis when it was given after the onset of the dis- 
ease, suggesting that the CD40L--CD40  interaction is only 
crucial for the priming of Thl cells and not for their expan- 
sion and secretion of IFN-%  The  most likely explanation 
for this is that IL-12 production, which has also been shown 
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stimulated by IFN-~/and therefore might not be dependent 
on cell-cell interactions (14). 
These data and conclusions have several clinical implica- 
tions.  For instance,  if the findings of this study can be re- 
peated  in other animal models  of Thl-mediated  (autoim- 
mune)  diseases,  one might speculate that the chances for a 
successful  treatment  with  anti-human  CD40L  in  estab- 
lished human autoimmune diseases  are not as good as ini- 
tially hoped. However, such treatment might still be of im- 
portance in the prevention  of transplant rejection, because 
in this specific situation the priming ofT helper subsets can 
be influenced.  In addition, this new insight into the mech- 
anism for the priming of Thl-type cells also opens a novel 
potential' therapeutic strategy for the treatment of opportu- 
nistic infections (Pneumocystis  carinii and intestinal  Cryptospo- 
ridium)  in hyper-IgM patients (22). Thus, from the data pre- 
sented,  one would predict that short-term IL-12 treatment 
of such patients during a period of infection should be suf- 
ficient for the priming of a Thl  T  cell response crucial for 
host  defense.  Such priming  would  not  be  necessary later 
because the CD40L-CD40 interaction does not seem to be 
critical in maintaining a Thl T  cell response. In conclusion, 
these data underscore the crucial role of the CD40L-CD40 
interaction  during the  ceil-cell  contact between  activated 
T  cells and APC in the priming of Thl  cells. 
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